Recommendations for the use of sapropterin in phenylketonuria.
Mol Genet Metab
; 106(3): 269-76, 2012 Jul.
Article
en En
| MEDLINE
| ID: mdl-22575621
ABSTRACT
Phenylketonuria (PKU) is an inherited disorder of phenylalanine (Phe) metabolism. Until recently, the only treatment for PKU was a Phe-restricted diet. Increasing evidence of suboptimal outcomes in diet-treated individuals, inconsistent PKU management practices, and the recent availability of tetrahydrobiopterin (BH(4)) therapy have fueled the need for new management and treatment recommendations for this metabolic disorder. BH(4), now available as sapropterin dihydrochloride (sapropterin), may offer the potential for improved metabolic control as well as enhanced dietary Phe tolerance in some PKU patients. A group of metabolic dietitians from North America convened in June 2011 to draft recommendations for the use of sapropterin therapy in PKU. Physicians with extensive experience in PKU management were invited at a later date to contribute to the development of these recommendations. Based on extensive clinical experience and current evidence, the present recommendations provide guidance from patient selection and determination of sapropterin response to the long-term management of patients on sapropterin therapy. Target Phe levels, nutritional adequacy, neurocognitive screening and adherence to treatment are addressed to optimize patient outcomes.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fenilcetonurias
/
Biopterinas
Tipo de estudio:
Guideline
Límite:
Child, preschool
/
Humans
País como asunto:
America do norte
Idioma:
En
Año:
2012
Tipo del documento:
Article